PDS Biotechnology Corporation
PDSB
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.49M
Close$
$0.21
28.5% downside
Current Fair Value
28.5% downsideOvervalued by 28.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.49 Million |
|---|---|
| Enterprise Value | $-1,216,090,661.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.74 |
| Beta | 1.45 |
| Outstanding Shares | 55,659,669 |
Return
| Return on Equity | 1.01% |
|---|---|
| Return on Assets | -0.41% |
| Return on Invested Capital | 228.54% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | -13.74 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.15 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | -3.59 |
| Debt to Equity | -1.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 343,600▲ 4.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.82%▲ 4.72% |
|---|---|
| Total Invested | $6.78M▲ 121.91% |
| Investors Holding | 53▲ 11.00% |
ESG Score
No data
About PDS Biotechnology Corporation
CEO: Frank Bedu-Addo